RESEARCH PAPER
Improving identification of women at high-risk for osteoporosis in primary care – results from 2,051 cases in a regional screening initiative
More details
Hide details
1
Department of Rehabilitation, Medical University, Lublin, Poland
2
Department of Biophysics, Faculty of Environmental Biology, University of Life Sciences, Lublin, Poland
3
University Hospital, NHS Trust, Oxford, United Kingdom
Corresponding author
Karolina Turżańska
Department of Rehabilitation, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
It is estimated that 80% of patients with low-trauma fractures leave the hospital without diagnosis and treatment for osteoporosis. Over 20% of hip fracture patients die within a year, and 25% are left dependent. The primary aim of the study is to evaluate the outcomes of a coordinated primary care screening programme designed to identify postmenopausal women at increased risk of osteoporotic fractures. The second aim is to assess the practical usefulness of FRAX as a triage tool for referral to specialist evaluation.
Material and methods:
The records of 2,051 women aged 50–69 years without a prior diagnosis of osteoporosis or osteopenia were analyzed. After initial screening at primary care, the 10-year fracture risk was assessed using FRAX. Eligible patients were referred to a specialist centre, where further diagnostics were performed, and recommendations made to the family physician.
Results:
In Stage I, 59.1% of women had a moderate (5–10%) or high (>10%) 10-year fracture risk. A total of 1,126 patients were referred to Stage II, and 850 completed the evaluation. Osteoporosis was diagnosed in 41.8%, osteopenia in 39.4%, and normal results was found in only 17.8%. FRAX >10% was associated with a higher probability of osteoporosis than FRAX 5–10%, but the association was weak. The cumulative risk of bone mineral density deficiency was higher in the high-risk group. Diagnosing low-trauma fractures in primary care had low sensitivity (15.9%) and high specificity (93.4%).
Conclusions:
The programme revealed a high prevalence of unrecognized osteoporosis and osteopenia in postmenopausal women. FRAX is a useful screening tool in primary care, but it does not replace DEXA. The results show the need for better education of primary care physicians and coordination of care to reduce the treatment gap in osteoporosis.
REFERENCES (22)
1.
Hsieh E, Bryazka D, Ong KL, et al. The global, regional, and national burden attributable to low bone mineral density, 1990–2020: an analysis of a modifiable risk factor from the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2025;7(12):e873-e894.
https://doi.org/10.1016/S2665-....
2.
Roux C, Thomas T, Paccou J, et al. Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study. JBMR plus. 2021;5(7):e10507.
https://doi.org/10.1002/jbm4.1....
4.
Chen Y, Guo Y, Tong G, et al. Combined nutritional status and activities of daily living disability is associated with one-year mortality after hip fracture surgery for geriatric patients: a retrospective cohort study. Aging Clin Exp Res. 2024;36(1):127.
https://doi:10.1007/s40520-024....
5.
van Oostwaard M, Marques A. Osteoporosis and the Nature of Fragility Fracture: An Overview. In: Hertz K, Santy-Tomlinson J, editors. Fragility Fracture and Orthogeriatric Nursing. Perspectives in Nursing Management and Care for Older Adults. Cham: Springer; 2024. p. 17–34.
https://doi.org/10.1007/978-3-....
6.
Curtis EM, Dennison EM, Cooper C, et al. Osteoporosis in 2022: Care gaps to screening and personalised medicine. Best Pract Res Clin Rheumatol. 2022;36(3):101754.
https://doi:10.1016/j.berh.202....
8.
Harvey NC, Al-Daghri N, Beaudart C, et al. Barriers and solutions for global access to osteoporosis management: a Position Paper from the International Osteoporosis Foundation. Osteoporos Int. 2025;36(9):1495–1507.
https://doi:10.1007/s00198-025....
9.
Schini M, Johansson H, Harvey NC, et al. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024;47(3):501–511.
https://doi:10.1007/s40618-023....
10.
Kanis, JA, Harvey NC, Johansson H, et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020;32:187–196.
https://doi.org/10.1007/s40520....
11.
Ratnasingam J, Niyaz M, Mariyappan S, et al. Age-dependent FRAX-based assessment and intervention thresholds for therapeutic decision making in osteoporosis in the Malaysian population. Arch Osteoporos. 2024;19(1):18.
http://doi:10.1007/s11657-024-....
12.
Naseri A, Bakhshayeshkaram M, Salehi S, et al. FRAX-derived intervention and assessment thresholds for osteoporosis in ten Middle Eastern countries. Arch Osteoporos. 2024;19(1):41.
https://doi:10.1007/s11657-024....
13.
Głuszko P, Sewerynek E, Misiorowski W, et al. Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022. Endokrynol Pol. 2023;74(1):5–15.
https://doi:10.5603/EP.a2023.0....
14.
McCloskey E, Rathi J, Heijmans S, et al. Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe. Arch Osteoporos. 2022;17(1):20.
https://doi:10.1007/s11657-021....
15.
Salminen H, Piispanen P, Toth-Pal E. Primary care physicians’ views on osteoporosis management: a qualitative study. Arch Osteoporos. 2019;14(1):48.
https://doi:10.1007/s11657-019....
16.
Salawati EM, Alqulayti WM. Family Physicians’ Knowledge and Practice of FRAX® in the Management of Osteoporosis in Jeddah, Saudi Arabia. Cyprus J Med Sci. 2024;9(2):107–112.
https://doi:10.4274/cjms.2024.....
17.
Elias N, Ribeiro JEG, Campinho LA, et al. Review of Osteoporotic Fractures: Occurrence, Prevention, and Consequences. Rev Bras Ortop (Sao Paulo). 2025;60(2):s00441789220.
https://doi:10.1055/s-0044-178....
18.
Simpkins RC, Downs TN, Lane MT. FRAX Prediction With and Without Bone Mineral Density Testing. Fed Pract. 2017;34(5):40–43.
19.
Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58.
https://doi:10.1007/s11657-022....
20.
Thériault G, Limburg H, Klarenbach S, et al. Recommendations on screening for primary prevention of fragility fractures. CMAJ. 2023;195(18):E639-E649.
https://doi:10.1503/cmaj.22121....
22.
Edwards FD, Grover ML, Cook CB, et al. Use of FRAX as a determinant for risk-based osteoporosis screening may decrease unnecessary testing while improving the odds of identifying treatment candidates. Women’s Health Issues. 2014;24(6):629–634.
https://doi.org/10.1016/j.whi.....